EGA
LSTA icon

Eagle Global Advisors’s Lisata Therapeutics LSTA Stock Holding History

Eagle Global Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,823
Closed -$127K – 394
2016
Q3 		$127K Buy
+1,823
New +$147K ﹤0.01% 333

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Eagle Global Advisors's LSTA Position: Q4 2016 in Review

Eagle Global Advisors sold out of Lisata Therapeutics (LSTA) in Q4 2016, closing a stake of 1,823 shares — an estimated $127K sold.

Eagle Global Advisors first reported a position in LSTA in Q3 2016 and held it in 1 quarter. The position peaked at $127K in Q3 2016. 30 funds tracked by Wall St. Rank hold LSTA as of Q4 2016.

  • Eagle Global Advisors reported no remaining Lisata Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 1,823 Lisata Therapeutics shares in Q4 2016, an estimated $127K.
  • Eagle Global Advisors first reported a position in Lisata Therapeutics in Q3 2016 and held it in 1 quarter.
  • Eagle Global Advisors's Lisata Therapeutics position peaked at $127K in Q3 2016.
  • 30 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q4 2016.

Based on Eagle Global Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.